Business ❯Pharmaceutical Industry ❯Drug Development ❯Clinical Trials

Aduhelm Study

Biogen Discontinues Controversial Alzheimer's Drug Aduhelm

Company to Redirect Resources Toward Other Drug Candidates After Internal Review